|Awarded On||November 18, 2021|
|Title||Recruitment of Established Investigators|
|Award Mechanism||Recruitment of Established Investigators|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||James Harbour|
|Cancer Sites||Eye and Orbit|
|Summary of Goals and Objectives||
The success of checkpoint inhibitors for treating metastatic cutaneous melanoma and other cancers has generated interest in immunologic therapies; however, only a subset of cancers responds to such therapies, whereas many cancers are unresponsive. While low tumor mutation burden may explain in part why cancer types are immunologically “cold,” recent discoveries suggest that active immune suppression by the tumor plays an important role. It is unclear in most cases how cancer cells create such an inhibitory immune microenvironment. Elucidating the mechanisms of this immunosuppression could generate novel therapies. One cancer ...